CLINICAL_TRIALS
trial_result
· 2017-03-06
Clinical Trial Update: Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174) [Phase 2]
Summary
A Phase 2 safety and pharmacokinetics study of nintedanib (BIBF 1120) in Japanese patients with idiopathic pulmonary fibrosis; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2017-03-06